2006
Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors
1997
Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age
Krumholz H, Vaccarino V, Ellerbeck E, Kiefe C, Hennen J, Kresowik T, Gold J, Jencks S, Radford M. Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age. The American Journal Of Cardiology 1997, 79: 581-586. PMID: 9068512, DOI: 10.1016/s0002-9149(96)00819-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlabamaAngiotensin-Converting Enzyme InhibitorsConnecticutContraindicationsControlled Clinical Trials as TopicDecision MakingDiabetes ComplicationsDiureticsDrug PrescriptionsDrug UtilizationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIowaMaleMedicaidMultivariate AnalysisMyocardial InfarctionPatient DischargeRetrospective StudiesStroke VolumeTachycardia, VentricularUnited StatesVentricular Function, LeftWisconsinConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionDischarge medicationsVentricular functionEnzyme inhibitorsLeft ventricular ejection fractionAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsVentricular Enlargement (SAVE) trialCongestive heart failureVentricular ejection fractionYears of ageEligible patientsPatient characteristicsAppropriate patientsDiabetes mellitusEjection fractionHeart failureLoop diureticsMultivariable analysisVentricular tachycardiaIdeal patientObservational studyPatients